In a small phase 2randomized controlled trial, TOL-463 as an insert or gel achieved clinical cure rates of 50 to 59% against BV and 81 to 92% against VVC in women who had one or both conditions.[4][2][1] It was effective and safe in the study, though it was without indication of superiority over other antifungal medications for VVC.[2][1] The cure rates against BV with TOL-463 were said to be comparable to those with recently approved antibiotic treatments like single-dose oralsecnidazole (58%) and single-dose metronidazole vaginal gel (41%).[1]
^ abcdeNyirjesy P, Brookhart C, Lazenby G, Schwebke J, Sobel JD (April 2022). "Vulvovaginal Candidiasis: A Review of the Evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections Treatment Guidelines". Clin Infect Dis. 74 (Suppl_2): S162–S168. doi:10.1093/cid/ciab1057. PMID35416967.